Breaking News

Financial Report: Emergent BioSolutions

By Kristin Brooks | March 7, 2014

2013 revenues up 11%

Emergent BioSolutions

4Q Revenues: $98.1 million (+4%)

4Q Earnings: $15.2 million (-6%)

FY Revenues: $312.7 million (+11%)

FY Earnings: $31.1 million (+32%)

Comments: For the year, product sales were $257.9 million, up 19%, driven by the biodefense business with strong performance reflected by the increased BioThrax doses shipped and sales of newly acquired medical countermeasure RSDL.
Contracts and grants revenues were $54.8 million, down 17% primarily due to decreased revenue associated with BioThrax PEP and PreviThrax development activities, offset by revenue associated with CIADM contract with BARDA. R&D expenses were flat at $119.9 million for the year. In the quarter, the company announced the acquisition of Cangene Corp., which added three Biodefense countermeasures, four commercial products, an infrastructure focused on hospitals and specialty clinics, and a growing contract manufacturing and fill/finish business.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success